Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Rentschler Biopharma is a leading global contract development and manufacturing organization (CDMO) with a strong focus on client projects. With over 150 years of experience in producing pharmaceuticals and 40 years in biotechnology, the company offers end-to-end solutions for the development and cGMP manufacturing of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and advanced therapy medicinal products (ATMPs). They support clients from early-stage clinical development through to commercial market supply, emphasizing quality, reliability, and partnership.
Global headquarters, housing corporate functions, extensive R&D laboratories, and large-scale cGMP biopharmaceutical manufacturing facilities.
State-of-the-art single-use and stainless-steel bioreactor capacities, advanced fill & finish capabilities, and dedicated facilities for process development and analytics.
A science-driven, collaborative environment focused on innovation, quality, and customer success. Strong emphasis on employee development and expertise in bioprocessing.
The Laupheim site is the historical heart of the company and its largest operational hub, driving innovation and global manufacturing excellence.
Rentschler Biopharma supports clients worldwide through its strategically located sites in Germany (Laupheim), the USA (Milford, MA), and the UK (Stevenage). These locations enable the company to offer comprehensive CDMO services, including process development, cGMP manufacturing, and fill & finish, catering to global clinical trial needs and commercial supply chains for biopharmaceuticals and advanced therapies.
Erwin-Rentschler-Strasse 21
Laupheim
Baden-Württemberg
Germany
Address: 201 South Street, Milford, MA 01757, USA
Serves the North American biopharmaceutical market, providing development and manufacturing services, and acts as a key hub for US-based clients.
Address: Cell and Gene Therapy Catapult Manufacturing Centre, Gunnels Wood Road, Stevenage, SG1 2FX, UK
Supports the growing ATMP market in the UK and Europe, providing specialized expertise and manufacturing capacity for cell and gene therapy developers.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Rentschler Biopharma' leadership includes:
Rentschler Biopharma has been backed by several prominent investors over the years, including:
Rentschler Biopharma has maintained a stable executive team with a key focus on strategic growth. Any recent significant changes would typically be announced via their official press channels.
Discover the tools Rentschler Biopharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Rentschler Biopharma commonly uses the firstname.lastname@rentschler-biopharma.com email format. Variations might exist, but this is a prevalent structure for companies of its type.
firstname.lastname@rentschler-biopharma.com
Format
john.doe@rentschler-biopharma.com
Example
85%
Success rate
Rentschler Biopharma Website • June 26, 2024
Rentschler Biopharma SE and Sumitomo Pharma Co., Ltd. have entered into a Strategic Collaboration Agreement for a late-stage biopharmaceutical product candidate. Rentschler Biopharma will leverage its extensive expertise in cGMP manufacturing and regulatory support for Sumitomo Pharma’s development candidate....more
Rentschler Biopharma Website • May 14, 2024
Rentschler Biopharma SE announced the appointment of Alexander Dettmer as Chief Financial Officer (CFO), effective May 1, 2024. He brings extensive experience in finance and the life sciences industry....more
Rentschler Biopharma Website • April 16, 2024
Rentschler Biopharma SE and CelluLicon, a clinical-stage biotech company, are partnering to advance the manufacturing of CelluLicon's novel protein-based cell therapy candidate for cancer treatment. Rentschler Biopharma will provide CDMO services for process development and cGMP manufacturing....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Rentschler Biopharma, are just a search away.